Microbiome transplants can reprogram immune system to attack tumors
‘For the first time in the world, we have successfully fought cancerous tumors by changing the gut microbiome,’ says oncologist.
Image of gut microbiome via Shutterstock.com
The results were published in the peer-reviewed journal
Science by a research team led by senior GI oncologist Dr. Ben Boursi, senior oncologist Dr. Gal Markel and MD-PhD student Erez Baruch.
“For the first time in the world, we have successfully fought cancerous tumors by changing the gut microbiome,” Boursi said.
“Currently, immunotherapy works for only 40 percent to 50 percent of patients. We anticipate that with the help of this revolutionary treatment, we will see as many patients as possible transforming from non-responders to responders,” he said.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Single-cell Sequencing Services and Technologies Market, 2020-2030 report features an extensive study of the current landscape and the future opportunities associated with single-cell sequencing services/technologies.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as number of single-cell samples sequenced annually, average cost of sequencing, and growth trends across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2020-2030.
BRAF-mutant metastatic colorectal cancer (mCRC), a multicenter randomized trial showed.
Median PFS increased from 2.0 months with irinotecan and cetuximab (Erbitux) to 4.2 months with the same two drugs plus the BRAF inhibitor vemurafenib (Zelboraf). Overall survival (OS) improved numerically from 5.9 months with two drugs to 9.6 months with the addition of vemurafenib.
Objective response rate (ORR) and disease control rate (DCR) were three to four times higher with the three-drug combination, Scott Kopetz, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston, and co-authors reported in the This supports the finding that the combination of BRAF and EGFR inhibition can provide clinical benefit in a setting where the activity of either BRAF or EGFR inhibition alone is minimal, the authors said of their findings. Indeed, in the control arm, the median PFS of 2 months corresponded with the first restaging and no patients demonstrated any regression in ct [circu
Yeti roars, SolarWinds deflates: The best and worst performing Austin stocks in 2020 bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
We don’t typically think of cancer as a disease of the young. But the truth is that it can strike anyone, from young children to elderly adults. And if new research is any indication, there is one age group we should pay extra special attention to: adolescents and young adults.
A large December 2020 study in
JAMA Open Network sheds light on some concerning statistics–the increase in cancer rates among people ages 15 to 39. Researchers found that between 1973 and 2015, cancer rates increased by 30%, with breast cancer and testicular cancer being the most common diagnoses. Every year since 2006, 70,000 or more people in this age group in the U.S. have been diagnosed with some form of cancer, a lower number than in older adults but a higher number than in children. The American Cancer Society notes that 5% of all cancers are diagnosed in people between 20 and 39 years old.